安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAR 安飞士

休市中 08-23 16:00:00 EDT

87.92

+3.03

+3.57%

盘后87.92

+0.000.00%

19:26 EDT

最高89.28	最低85.10	成交量44.62万
今开86.17	昨收84.89	日振幅4.93%
总市值31.36亿	流通市值15.34亿	总股本3,566万
成交额3,916万	换手率2.56%	流通股本1,745万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":87.92,"timestamp":1724443200000,"preClose":84.89,"halted":0,"volume":446204,"hourTrading":{"tag":"盘后","latestPrice":87.92,"preClose":87.92,"latestTime":"19:26 EDT","volume":5667,"amount":498221.54,"timestamp":1724455615359},"delay":0,"floatShares":17452930,"shares":35664115,"eps":21.31042,"marketStatus":"休市中","marketStatusCode":7,"change":3.03,"latestTime":"08-23 16:00:00 EDT","open":86.17,"high":89.28,"low":85.095,"amount":39155855.62504,"amplitude":0.049299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":21.31042,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":0,"adjPreClose":84.89,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":85.99,"preClose":84.89,"latestTime":"09:28 EDT","volume":1261,"amount":108385.44678000001,"timestamp":1724419680003},"postHourTrading":{"tag":"盘后","latestPrice":87.92,"preClose":87.92,"latestTime":"19:26 EDT","volume":5667,"amount":498221.54,"timestamp":1724455615359},"volumeRatio":1.5724397683535625,"optionData":{"bulkOrders":[{"symbol":"CAR","call":true,"expireDate":1725595200000,"strike":"93.0","timestamp":1724421763969,"price":1,"volume":1499,"amount":149900,"type":"-"}]},"impliedVol":0.5239,"impliedVolPercentile":0.4206},"requestUrl":"/m/hq/s/CAR/tweets","defaultTab":"tweets","newsList":[{"id":"2460837009","title":"百时美施贵宝(BMY.US)CAR-T疗法监管申请获欧盟接受","url":"https://stock-news.laohu8.com/highlight/detail?id=2460837009","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460837009?lang=zh_cn&edition=full","pubTime":"2024-08-20 21:04","pubTimestamp":1724159049,"startTime":"0","endTime":"0","summary":"8月20日，百时美施贵宝(BMY.US)宣布，欧洲药品管理局(EMA)已完成其CAR-T细胞疗法Breyanzi(lisocabtagene maraleucel；liso-cel)新适应症申请的验证。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240820/20240820210538_93022.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240820/20240820210538_93022.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1167279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0868494617.USD","LU1291159041.SGD","LU2242652126.USD","IE0002141913.USD","BK4559","BK4588","LU2125154778.USD","BMY","LU0061475181.USD","LU2125154935.USD","LU0306807586.USD","IE00BJJMRZ35.SGD","BK4581","LU1718418525.SGD","LU0985481810.HKD","LU1670710661.SGD","LU0225284248.USD","LU1670711123.USD","LU0456855351.SGD","IE00BSNM7G36.USD","LU1571399168.USD","BK4022","BK4532","BK4007","IE00BJT1NW94.SGD","LU0225771236.USD","LU1261432733.SGD","IE0009355771.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","BK4585","BK4230","LU0882574055.USD","LU2242646821.SGD","LU2133065610.SGD","LU1585245621.USD","LU0114720955.EUR","LU0321505868.SGD","LU1074936037.SGD","BK4534","LU1093756325.SGD","LU0237698245.USD","LU1670710588.SGD","CAR","LU0306806265.USD","LU1670711040.USD","LU2360032135.SGD","LU1032466523.USD","LU0321505439.SGD","LU1989771016.USD"],"gpt_icon":0},{"id":"2461530508","title":"半年营收微增2.8%，华东医药投资“加减法”传递什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2461530508","media":"投资时间","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461530508?lang=zh_cn&edition=full","pubTime":"2024-08-20 14:52","pubTimestamp":1724136777,"startTime":"0","endTime":"0","summary":"仿制药产业高速发展期过后，华东医药更多依靠投资实现规模和业务范围的扩大标点财经、投资时间网研究员 李路华东医药股份有限公司（下称华东医药，000963.SZ）素有A股传统药白马企业之称，自2000年上市以来至2019年业绩保持了连续20年的增长状态，至今ROE也基本处于15%以上。在集采和医保谈判的大环境下，公司于2020年和20...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/O6v794Ckc9afdPGGW7xiKJ7NGk-5-oUKv8SeY6_nGrIckAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/O6v794Ckc9afdPGGW7xiKJ7NGk-5-oUKv8SeY6_nGrIckAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240820A054WY00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240820A054WY00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2460447725","title":"科济药业全球同类首创Claudin18.2 CAR-T舒瑞基奥仑赛注射液中国胃癌确证性II期临床试验完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2460447725","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460447725?lang=zh_cn&edition=full","pubTime":"2024-08-19 08:30","pubTimestamp":1724027400,"startTime":"0","endTime":"0","summary":"舒瑞基奥仑赛注射液是一种潜在全球同类首创的、靶向Claudin18.2的自体CAR-T细胞候选产品，主要治疗胃癌/食管胃结合部腺癌及胰腺癌，已发表的临床数据展示了其令人鼓舞的安全性和疗效。[4] 科济药业创始人、董事会主席、首席执行官、首席科学官李宗海博士表示：\"非常高兴舒瑞基奥仑赛注射液中国确证性II期临床试验顺利完成受试者的入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4485586_ZH85586_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["02171","BK1161","BK4230","BK1587","CAR","BK1574","BK1585","BK4022"],"gpt_icon":0},{"id":"2459155246","title":"“抄底”还是“冒进”？东北制药“押注”细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2459155246","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459155246?lang=zh_cn&edition=full","pubTime":"2024-08-16 19:13","pubTimestamp":1723806804,"startTime":"0","endTime":"0","summary":"本报（chinatimes.net.cn）记者于娜 北京报道混改后许久都没有并购动作的东北制药为何相中了一家聚焦实体瘤CGT领域的Biotech？近日，东北制药公告称拟收购北京鼎成肽源生物技术有限公司（下称“鼎成肽源”）70%股权，快速切入特异性细胞免疫治疗技术研究、产品开发和临床应用，培育新的业务和盈利增长点。此时恰逢大热的细...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OWpVJqKKTzxX94ExmT2LYC2YGVsqm0CwZwqwW5h94WpNMAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OWpVJqKKTzxX94ExmT2LYC2YGVsqm0CwZwqwW5h94WpNMAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240816A08KNZ00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240816A08KNZ00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["ADC","BK4230","BK4231","BK4022","06978","BK1574","BK4080","CAR","BK1161"],"gpt_icon":0},{"id":"2459420004","title":"安飞士盘中异动 早盘股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459420004","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459420004?lang=zh_cn&edition=full","pubTime":"2024-08-15 21:40","pubTimestamp":1723729243,"startTime":"0","endTime":"0","summary":"北京时间2024年08月15日21时40分，安飞士股票出现波动，股价大幅拉升5.19%。截至发稿，该股报88.70美元/股，成交量2.3507万股，换手率0.07%，振幅1.91%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体涨幅为2.34%。Avis 的服务对象为旅游业的高端商业和休闲分部，Budget 则面向重视性价比的客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815214047ab5dd8c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815214047ab5dd8c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"2459639492","title":"TCE双抗还得更火","url":"https://stock-news.laohu8.com/highlight/detail?id=2459639492","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459639492?lang=zh_cn&edition=full","pubTime":"2024-08-15 14:08","pubTimestamp":1723702086,"startTime":"0","endTime":"0","summary":"双抗赛道，从不缺热点。而这其中，当前最火热的无疑是TCE双抗。在血液瘤领域，市场对于TCE双抗的预期已经拉满。强生对于自家两款TCE双抗的销售额峰值，已经看到了50亿美元。2024年，TCE双抗在实体瘤领域也迎来了突破。尽管市场已经足够火热，但就目前而言，TCE双抗仍处于非常初级的阶段，不管是技术方向，还是适应症，都还有很大的突破空间。这意味着，TCE双抗还得更火。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/237774","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4022","CAR","BK4230"],"gpt_icon":0},{"id":"2459947261","title":"中国药企又创造出一个大药 | 见智研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2459947261","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459947261?lang=zh_cn&edition=full","pubTime":"2024-08-13 15:41","pubTimestamp":1723534916,"startTime":"0","endTime":"0","summary":"掀起TCE双抗的风潮？","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/f99d7cb4-6457-4fd7-a459-952c325e0470.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/f99d7cb4-6457-4fd7-a459-952c325e0470.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3723801","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3723801","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK4230","BK4097","OS","CAR","BK4211","BK4195","BK4022","CDC","PFS"],"gpt_icon":0},{"id":"2459939793","title":"安飞士盘中异动 急速跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459939793","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459939793?lang=zh_cn&edition=full","pubTime":"2024-08-13 00:57","pubTimestamp":1723481866,"startTime":"0","endTime":"0","summary":"北京时间2024年08月13日00时57分，安飞士股票出现波动，股价快速跳水5.04%。截至发稿，该股报82.58美元/股，成交量22.4003万股，换手率0.63%，振幅4.24%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体跌幅为0.80%。安飞士公司简介：Avis Budget Group Inc 是一家汽车租赁和汽车共享服务提供商。公司品牌包括 Avis、Budget 和 Zipcar。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813005746942000e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813005746942000e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","CAR","BK4022"],"gpt_icon":0},{"id":"2458166692","title":"安飞士2024财年第二财季实现净利润14.00百万美元，同比减少96.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458166692","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458166692?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:07","pubTimestamp":1723392423,"startTime":"0","endTime":"0","summary":"8月12日，安飞士公布财报，公告显示公司2024财年第二财季净利润为14.00百万美元，同比减少96.78%；其中营业收入为30.48亿美元，同比减少2.40%，每股基本收益为0.39美元。从资产负债表来看，安飞士总负债343.64亿美元，其中短期债务5.95亿美元，资产负债比为0.99，流动比率为0.86。机构评级：截至2024年8月12日，当前有8家机构对安飞士目标价做出预测，其中目标均价为132.62美元，其中最低目标价为95.00美元，最高目标价为175.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120007159590400c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120007159590400c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR"],"gpt_icon":0},{"id":"2458652700","title":"14款今年获批抗肿瘤药通过国谈初审 CAR-T疗法四度冲刺","url":"https://stock-news.laohu8.com/highlight/detail?id=2458652700","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458652700?lang=zh_cn&edition=full","pubTime":"2024-08-10 10:26","pubTimestamp":1723256807,"startTime":"0","endTime":"0","summary":"【14款今年获批抗肿瘤药通过国谈初审 CAR-T疗法四度冲刺】备受期待的新一轮国家医保谈判初审目录近日出炉。国家医保局官网公布了已通过初步形式审查的2024年国家医保目录，共涉及440个品种，与2023年相比，申报药品数量有所增加。14款今年新获批上市的抗肿瘤药被纳入初审名单，也不乏行内关注的重点品种，如因“天价”而备受关注的CAR-T疗法（嵌合抗原受体T细胞免疫疗法）、罕见病药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202408103153053978.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202408103153053978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2458025518","title":"20天斥资28亿元收入一家公司两款药，杭州药企为何密集扫货研发药？","url":"https://stock-news.laohu8.com/highlight/detail?id=2458025518","media":"浙商杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458025518?lang=zh_cn&edition=full","pubTime":"2024-08-09 20:11","pubTimestamp":1723205484,"startTime":"0","endTime":"0","summary":"点击上方蓝字每一个有商业梦想的人都会关注我们~7月中旬以来，华东医药已三度出手，短短20天内，收进两款药、一家药厂，交易总额超28亿。华东医药掌舵人吕梁，又拿下一款重磅药。8月4日，华东医药公告称，全资子公司华东医药（杭州）有限公司与北京艺妙神州医药科技有限公司（下称“艺妙神州”）签订了产品独家商业化合作协...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OTCR0rRpsczs0VuCh7tCtUvHfTezDYy23iYm0ikc3fm_IAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OTCR0rRpsczs0VuCh7tCtUvHfTezDYy23iYm0ikc3fm_IAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240809A09ET700","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240809A09ET700","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4022","BK4230","CAR"],"gpt_icon":0},{"id":"2458555987","title":"石药集团(01093)：首款基于mRNA-LNP的CAR-T细胞注射液(SYS 6020)获新适应症临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2458555987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458555987?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:37","pubTimestamp":1723192657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的首款基于mRNA-LNP技术，靶向B细胞成熟抗原的嵌合抗原受体-T细胞注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展系统性红斑狼疮适应症的临床试验。该产品为目前全球首款获批SLE临床试验的基于mRNA-LNP的细胞治疗产品。临床前研究显示，该产品可显著杀伤BCMA抗原阳性的骨髓瘤细胞，并具有良好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","LU0067412154.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU0880133367.SGD","IE00B543WZ88.USD","BK1141","LU0501845795.SGD","LU1807302812.USD","BK1515","LU1226287529.USD","BK4022","IE0008368742.USD","LU1152091754.HKD","LU0140636845.USD","SG9999004220.SGD","01093","LU1960683339.HKD","BK4230","BK1191","IE00B031HY20.USD","LU0326950275.SGD","LU0072913022.USD","LU1152091168.USD","BK1576","BK1521","CAR","BK1583","LU1008478684.HKD","IE0008369823.USD"],"gpt_icon":0},{"id":"2458588108","title":"石药集团(01093)1类CAR-T疗法获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2458588108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458588108?lang=zh_cn&edition=full","pubTime":"2024-08-09 10:25","pubTimestamp":1723170306,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月9日，中国国家药监局药品审评中心官网公示显示，石药集团中奇制药申报的1类新药SYS6020注射液获批临床，拟用于难治性活动性系统性红斑狼疮。资料显示，SYS6020作为一款基于mRNA-LNP的细胞治疗产品，可通过表达可特异性识别BCMA抗原的CAR，进而靶向识别患者体内BCMA阳性的细胞并对其进行杀灭。彼时，石药集团公告指出，除了多发性骨髓瘤适应症，SYS6020还潜在可用于治疗系统性红斑狼疮、重症肌无力等自身免疫性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0140636845.USD","LU0880133367.SGD","BK1521","LU0326950275.SGD","LU1960683339.HKD","LU1807302812.USD","SG9999004220.SGD","BK1515","BK4230","IE00B031HY20.USD","01093","LU1226287529.USD","BK4022","IE0008368742.USD","LU1152091754.HKD","LU1008478684.HKD","LU0067412154.USD","LU1993786604.SGD","BK1191","CAR","IE00B543WZ88.USD","IE0008369823.USD","LU0501845795.SGD","LU1152091168.USD","LU0072913022.USD"],"gpt_icon":0},{"id":"2458441813","title":"美国研究综述-Amphastar Pharmaceuticals、G1 Therapeutics、Upwork","url":"https://stock-news.laohu8.com/highlight/detail?id=2458441813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458441813?lang=zh_cn&edition=full","pubTime":"2024-08-09 00:55","pubTimestamp":1723136129,"startTime":"0","endTime":"0","summary":"    路透8月8日 - 华尔街证券分析师周四调整了对 Amphastar Pharmaceuticals、G1 Therapeutics 和 Upwork 等几家美国上市公司的评级和目标价。要点  * Amphastar Pharmaceuticals Inc   ：Piper Sandler 将目标价从 71 美元下调至 66 美元 * Charles River Laboratories International Inc   ：贝雅下调目标价至中性 * G1 Therapeutics Inc   ：H.C. Wainwright将其评级从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELH","TCPC","BLK","CAR","LU2264538146.SGD","LU2430703095.HKD","AIZ","LU1599440770.SGD","BCSF","APLS","AADI","BDSX","IE00B19Z9P08.USD","ASH","LU2430703251.USD","APP","ALLK","BLBD","LENZ","ACM","ADUS","ALB","ALLO","AZPN","ASIX","BOOT","BK4109","AKA","ATGE","BLNK","CE","BWMN","BARK","BYND","AGCO","AEVA","ARKO","LU1244550577.SGD","LU0566484027.USD","LU2430703178.SGD","BK4107","ATEX","ASLE","BXSL","LU0823414478.USD","ALEX","ACAD","ALIT","AZEK","AMPH"],"gpt_icon":1},{"id":"2457314808","title":"2024年医保目录调整初审名单来了：22款1类新药上半年刚获批，CAR-T产品几乎聚齐","url":"https://stock-news.laohu8.com/highlight/detail?id=2457314808","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457314808?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:52","pubTimestamp":1723125142,"startTime":"0","endTime":"0","summary":"每经记者：林姿辰    每经编辑：陈俊杰一年一度的医药行业盛会已经初筛出“入场嘉宾”了。8月7日晚间，国家医保局公开了《2024年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的申报药品名单》（以下简称“初步形式审查名单”），其中244个药品（通用名，下同）进入目录外药品名单，196个药品进入...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OtkkT3H7nBqoyJ4RADJoH0tS52xXzGI3anvK3F6OP8RqQAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OtkkT3H7nBqoyJ4RADJoH0tS52xXzGI3anvK3F6OP8RqQAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240808A09PUI00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240808A09PUI00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4022","CAR","BK4230"],"gpt_icon":0},{"id":"2457231496","title":"安飞士盘中异动 急速上涨5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457231496","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457231496?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:47","pubTimestamp":1723124875,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时47分，安飞士股票出现异动，股价大幅上涨5.23%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。安飞士股票所在的租赁服务行业中，整体涨幅为2.47%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808214756941ff763&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808214756941ff763&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2457821758","title":"美国研究综述-安进、Atkore、MoneyLion","url":"https://stock-news.laohu8.com/highlight/detail?id=2457821758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457821758?lang=zh_cn&edition=full","pubTime":"2024-08-08 00:34","pubTimestamp":1723048497,"startTime":"0","endTime":"0","summary":"    路透8月7日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括安进公司、Atkore公司和MoneyLion公司。要闻 * 安进公司  ：加拿大皇家银行将目标价从332美元上调至362美元 * Atkore Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。* MoneyLion   ：Needham将目标价从100美元下调至70美元 * Progyny Inc   ：BTIG将其评级从 \"买入 \"下调至 \"中性\"。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABL","AVNT","IE00B19Z4B17.USD","AMWL","ANAB","AZPN","AMGN","ARCT","ADTN","AZTA","AHCO","BK4548","ADUS","AXON","CAR","ASH","LU1023059063.AUD","AIRG","IE00BJT1NW94.SGD","AGL","BK4109","ASPI","ARMK","BBWI","BK4006","IE0031619046.USD","LU0122379950.USD","ALAB","AVB","LU1989773731.SGD","AMH","BEAM","GOLF","AESI","BWIN","AEE","AEP","ALGT","ACM","BAX","ATKR","ACAD","ATI","CELH","LU0289739699.SGD","IE00B7SZLL34.SGD","LU1057294990.SGD","ACA","IE00B3S45H60.SGD","ALIT"],"gpt_icon":1},{"id":"2457849704","title":"400亿杭州药企，28亿密集扫货","url":"https://stock-news.laohu8.com/highlight/detail?id=2457849704","media":"21世纪商业评论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457849704?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:26","pubTimestamp":1723037184,"startTime":"0","endTime":"0","summary":"记者丨韩璐 编辑丨陈晓平 谭璐华东医药掌舵人吕梁，又拿下一款重磅药。8月4日晚间，华东医药公告称，与艺妙神州签约，获得药物IM19在中国大陆的独家商业化权益，其是一款自体CAR-T候选产品。这笔交易总价10.75亿元，吕梁团队先付出1.25亿元首付款，后续注册及销售里程碑付款，最高可达9.5亿元。这是吕梁二度引入CAR-T产品，...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OWasoTUbi_6qsNC1JcPlv9UH7B_QzKXiRrFiOqMJtuN7wAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OWasoTUbi_6qsNC1JcPlv9UH7B_QzKXiRrFiOqMJtuN7wAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240807A09NQD00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240807A09NQD00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4230","CAR","BK4022"],"gpt_icon":0},{"id":"2457882895","title":"美国研究综述-安进、Atkore、Moneylion","url":"https://stock-news.laohu8.com/highlight/detail?id=2457882895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457882895?lang=zh_cn&edition=full","pubTime":"2024-08-07 16:03","pubTimestamp":1723017814,"startTime":"0","endTime":"0","summary":"    路透8月7日 - 华尔街证券分析师周三调整了对安进、Atkore 和 Moneylion 等几家美国上市公司的评级和目标价。要闻             * 安进公司  ：加拿大皇家银行将其目标价从332美元上调至362美元             * Atkore Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","ALAB","BCC","CRBU","BRKR","CAR","ALGT","BK4020","AVNT","BL","IE0002141913.USD","AZPN","AMH","BAX","BEAM","CERT","CBT","LU0868494708.USD","ACAD","ATKR","BBWI","IE00B7SZL793.SGD","AEP","IE00B775SV38.USD","BLDR","ATI","BK4149","ANAB","AZTA","BK4090","LU1894683348.USD","LU2098885051.SGD","ADTN","BK4566","LU1989773731.SGD","ALIT","BRBR","BBIO","H","ADUS","XAIR","BWIN","CAT","LUMN","AMGN","ARMK","AMWL","RDDT","BR","BLMN"],"gpt_icon":1},{"id":"2457612855","title":"Avis Budget Group公司: JP摩根将目标价从205美元下调至175美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457612855","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457612855?lang=zh_cn&edition=full","pubTime":"2024-08-07 11:22","pubTimestamp":1723000971,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4230","BK4022","CAR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0962},{"period":"3month","weight":-0.2144},{"period":"6month","weight":-0.163},{"period":"1year","weight":-0.6163},{"period":"ytd","weight":-0.504}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.是一家在特拉华州成立，总部位于新泽西州帕西帕尼市的公司。艾维士·巴吉集团为全球企业和消费者提供汽车和卡车租赁和配套服务。该公司经营着两家全球汽车租赁行业中最知名的品牌Avis和Budget。 Avis是一家领先的汽车租赁供应商，定位于服务旅游业的优质商业和休闲领域，而Budget是一家领先的汽车租赁供应商，业务主要集在该行业中更具价值意识的部分。该公司是领先的汽车租赁运营商，在北美，澳大利亚，新西兰和其他地区都有业务服务，该公司授权在世界各地以Avis和Budget品牌经营的国家就有超过180个多个。该公司通常在机场汽车租赁收入中占有主要份额，并运营着美国主要的卡车租赁业务之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.012765},{"month":2,"riseRate":0.642857,"avgChangeRate":0.055699},{"month":3,"riseRate":0.642857,"avgChangeRate":0.042142},{"month":4,"riseRate":0.642857,"avgChangeRate":0.012091},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.006618},{"month":6,"riseRate":0.5,"avgChangeRate":0.008098},{"month":7,"riseRate":0.571429,"avgChangeRate":0.042418},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.001236},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.037867},{"month":10,"riseRate":0.769231,"avgChangeRate":0.153852},{"month":11,"riseRate":0.692308,"avgChangeRate":0.064181},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.03046}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}